- Home
- GNL vs NKTR Comparison
GNL vs NKTR Comparison
Compare GNL & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNL | NKTR |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | GNL | NKTR |
|---|---|---|
| Price | $8.88 | $70.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $9.67 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $6.77 | $21.02 |
| 52 Week High | $10.04 | $109.00 |
Technical Indicators
Market Signals| Indicator | GNL | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 54.99 |
| Support Level | $8.12 | $64.30 |
| Resistance Level | $9.66 | $76.78 |
| Average True Range (ATR) | 0.22 | 3.47 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 12.50 | 47.61 |
Price Performance
Historical ComparisonAbout GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.